Welcome to our dedicated page for Merus SEC filings (Ticker: MRUS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Merus N.V. filings document the company's oncology-antibody business, common-share capital structure, and completed acquisition process involving Genmab. The record includes Form 8-K material-event disclosures for the transaction agreement and completion of an acquisition or disposition of assets, along with disclosures concerning shareholder voting matters, governance matters, and capital-structure changes.
The company’s Form 15-12G records the termination of registration of Merus N.V. common shares under Section 12(g) and suspension of Exchange Act reporting duties under Sections 13 and 15(d). It identifies the common shares with €0.09 nominal value per share, reports zero holders of record as of the certification date, and shows Merus B.V. acting as successor to Merus N.V.
Peter B. Silverman, COO & General Counsel of Merus N.V. (MRUS), executed a planned transaction under Rule 10b5-1 on June 20, 2025. The transaction involved:
- Exercise of 34,000 stock options at $18.61 per share
- Immediate sale of all 34,000 shares at a weighted average price of $52.76 (range: $52.44-$53.06)
- Retained 23,500 unexercised options from original February 14, 2020 grant
This transaction was conducted according to a pre-established Rule 10b5-1 trading plan adopted on March 20, 2025. The exercised options were fully vested, with an original expiration date of February 14, 2030. The sale represents a significant realization of gains, with approximately $1.16 million in gross proceeds before accounting for the exercise cost of $632,740.